{"denoms":[{"counts":[{"groupId":"BG000","value":"354"},{"groupId":"BG001","value":"355"},{"groupId":"BG002","value":"709"}],"units":"Participants"}],"groups":[{"description":"Arm A: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with h bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.","id":"BG000","title":"Velcade Lenalidomide Dexamethasone (VRd)"},{"description":"Arm B: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with subcutaneous daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by subcutaneous daratumumab in combination with lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.","id":"BG001","title":"Daratumumab + VRd (D-VRd)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.12","value":"58.1"},{"groupId":"BG001","spread":"7.81","value":"58.7"},{"groupId":"BG002","spread":"7.96","value":"58.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"149"},{"groupId":"BG001","value":"144"},{"groupId":"BG002","value":"293"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"205"},{"groupId":"BG001","value":"211"},{"groupId":"BG002","value":"416"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"50"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"254"},{"groupId":"BG001","value":"242"},{"groupId":"BG002","value":"496"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"163"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"323"},{"groupId":"BG001","value":"330"},{"groupId":"BG002","value":"653"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"30"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"47"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"165"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"243"},{"groupId":"BG001","value":"235"},{"groupId":"BG002","value":"478"}]}],"title":"White Non-Hispanic"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}],"title":"Czechia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"12"}]}],"title":"Switzerland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"102"}]}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"59"}]}],"title":"Greece"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"57"}]}],"title":"Netherlands"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"33"}]}],"title":"Turkey"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"17"}]}],"title":"Belgium"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"9"}]}],"title":"Norway"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"19"}]}],"title":"Denmark"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"14"}]}],"title":"Poland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"150"}]}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"72"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"153"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"}]}],"title":"Germany"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.41","value":"3"},{"groupId":"BG001","spread":"4.46","value":"2.2"},{"groupId":"BG002","spread":"8.66","value":"2.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Time Since Initial Diagnosis (months)","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"178"},{"groupId":"BG001","value":"186"},{"groupId":"BG002","value":"364"}],"title":"I"},{"measurements":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"114"},{"groupId":"BG002","value":"239"}],"title":"II"},{"measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"105"}],"title":"III"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"unknown"}]}],"description":"The International Staging System (ISS) for myeloma was published by the International Myeloma Working Group (a lower stage indicates less progressed disease):\n\nStage I: β2-microglobulin (β2M) \\< 3.5 mg/L, albumin \\>= 3.5 g/dL Stage II: β2M \\< 3.5 mg/L and albumin \\< 3.5 g/dL; or β2M 3.5 mg/L - 5.5 mg/L irrespective of the serum albumin\n\nStage III: β2M ≥ 5.5 mg/L.\n\nHigher stages indicate more advanced disease and/or poorer prognosis.\n\nData is the ISS result assessed at the time of randomization.","paramType":"COUNT_OF_PARTICIPANTS","title":"Stage of Disease (ISS)","unitOfMeasure":"Participants"}]}